Taysha Gene Therapies, Inc. (TSHA) – What Are Researchers Saying About This Stock?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been given an average rating of “Buy” by the fifteen analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, twelve have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $12.77.

TSHA has been the topic of several research analyst reports. Wolfe Research assumed coverage on shares of Taysha Gene Therapies in a research report on Thursday, September 17th. They issued an “outperform” rating on the stock. The Goldman Sachs Group lifted their target price on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, September 21st.

Taysha Gene Therapies Price Performance

NASDAQ:TSHA opened at $4.13 on Friday. Taysha Gene Therapies has a 1-year low of $3.45 and a 1-year high of $7.30. The company has a current ratio of 17.76, a quick ratio of 17.76 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.35 billion, a PE ratio of -9.83 and a beta of 1.19. The firm has a fifty day simple moving average of $4.82 and a 200 day simple moving average of $5.31.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, research analysts expect that Taysha Gene Therapies will post -0.52 EPS for the current fiscal year.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of hedge funds have recently made changes to their positions in TSHA. Sterling Capital Management LLC grew its stake in Taysha Gene Therapies by 945.6% during the third quarter. Sterling Capital Management LLC now owns 8,804 shares of the company’s stock worth $43,000 after purchasing an additional 7,962 shares during the period. R Squared Ltd acquired a new position in Taysha Gene Therapies in the first quarter valued at approximately $50,000. Y Intercept Hong Kong Ltd acquired a new position in Taysha Gene Therapies in the first quarter valued at approximately $51,000. Principal Financial Group Inc. lifted its stake in Taysha Gene Therapies by 26.2% in the first quarter. Principal Financial Group Inc. now owns 16,185 shares of the company’s stock valued at $72,000 after buying an additional 3,362 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Taysha Gene Therapies during the 3rd quarter worth approximately $81,000. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc is a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system. The company uses adeno-associated virus (AAV) delivery technologies and other genetic medicine approaches to address disorders that currently have limited or no effective treatment options.

Taysha’s development programs have included TSHA-102 for Rett syndrome, TSHA-101 for GM1 gangliosidosis and TSHA-120 for giant axonal neuropathy.